ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

HALO Halozyme Therapeutics Incorporated

38.02
-0.36 (-0.94%)
Apr 17 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 733,857
Bid Price 37.00
Ask Price 41.06
News -
Day High 38.78

Low
29.85

52 Week Range

High
45.00

Day Low 37.9817
Share Name Share Symbol Market Stock Type
Halozyme Therapeutics Incorporated HALO NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.36 -0.94% 38.02 19:00:00
Open Price Low Price High Price Close Price Previous Close
38.45 37.9817 38.78 38.02 38.38
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
10,270 733,857 US$ 38.28 US$ 28,094,864 - 29.85 - 45.00
Last Trade Type Quantity Price Currency
16:17:16 formt 31,911 US$ 38.02 USD

Halozyme Therapeutics Incorporated Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
4.82B 126.82M - 829.25M 281.59M 2.22 17.12
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Halozyme Therapeutics News

Date Time Source News Article
3/04/202415:13Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statements
2/28/202417:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/28/202415:07Edgar (US Regulatory)Form 144 - Report of proposed sale of securities
2/27/202416:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/27/202416:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/27/202416:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/27/202415:08Edgar (US Regulatory)Form 144 - Report of proposed sale of securities
2/27/202407:30PR Newswire (US)Halozyme to Participate in Upcoming Investor Conferences
2/20/202417:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/20/202417:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/20/202417:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/20/202417:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No HALO Message Board. Create One! See More Posts on HALO Message Board See More Message Board Posts

Historical HALO Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week39.2539.9237.981738.96976,327-1.23-3.13%
1 Month40.5242.3037.981739.97881,341-2.50-6.17%
3 Months35.0242.6433.1538.431,078,5593.008.57%
6 Months36.5242.8232.8337.531,168,9061.504.11%
1 Year36.2545.0029.8537.381,103,9241.774.88%
3 Years45.8559.4629.8541.201,102,995-7.83-17.08%
5 Years16.6959.4612.7134.701,198,69821.33127.80%

Halozyme Therapeutics Description

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Your Recent History

Delayed Upgrade Clock